Registration No. 195 325 /2004

Zinoxime ®

Cefuroxime for Injection USP

Composition:

Zinoxime 750 mg I.M./I.V.: The vial contains Sterile Cefuroxime Sodium USP equivalent to 750 mg of Cefuroxime.
Zinoxime 1.5 g I.V.: The vial contains Sterile Cefuroxime Sodium USP equivalent to 1.5 g of Cefuroxime.

Properties:

Zinoxime is a brand name of Cefuroxime for injection, which is a second generation cephalosporin antibiotic. It has similar activity as that of first generation cephalosporins but it is resistant to most beta-lactamases produced by Gram-negative bacteria. It is administered as intravenous or deep intramuscular injection. The plasma half-life of Cefuroxime is about 70 minutes. Its half-life is generally extended in neonates and in patients with renal diseases. It achieves the therapeutic concentrations in Cerebrospinal fluid (CSF) when the meninges are inflamed. Cefuroxime crosses the placenta and has also been detected in breast milk.

Indications:

Zinoxime is indicated in following infections:
- Lower respiratory tract infections.
- Ear, nose and throat infections.
- Skin and skin structure infections.
- Urinary tract infections.
- Obstetric and gynaecological infections.
- Meningitis.
- Gonorrhoea.
- Septicaemia.
- Bone and joint infections.

Contraindications:

Zinoxime is contraindicated in patients with known hypersensitivity to cephalosporin class of antibiotics.

Warnings:

Before giving injection of **Zinoxime,** hypersensitivity of the patient to Cephalosporins must be determined. The treatment must be stopped if allergic reactions occur. Special care to be taken in patients with known allergy to penicillins.

Dosage and Administration:

Zinoxime is given by I.M. or I.V. injection.
Adults: Moderate infections generally respond to 750 mg three times a day by I.M. or I.V. injection.
In severe infections, dose can be increased to 1.5 g three times a day by I.V. injection. The frequency of injections can be increased to four times, giving a total dose of 3-6 g per day.
Infants, Children and Neonates: On average the daily dose is 30-100 mg/kg of body weight divided in three or four doses for infants and children and in two or three doses for neonates.

Precautions:

The dose of **Zinoxime** should be reduced and the renal function should be monitored in patients with renal impairment.
It should be given with caution to patients who are already taking diuretics as this combination may affect renal functions.
It should be given with caution in early months of pregnancy.

Side Effects:

Allergic reactions: Skin eruptions and fever.
Haematological: Decreased haemoglobin, eosinophilia.
Hepatic functions: Transient rise in liver enzymes.
Gastrointestinal disturbances.
Pain at I.M. site.

Pharmaceutical Precautions:

Keep at room temperature (15 - 30 °C).
Keep contents in the carton until consumed.

Presentations:

Zinoxime 750 mg I.M. /I.V.: A carton containing one vial.
Zinoxime 1.5 g I.V.: A carton containing one vial.

Reconstitution for injection:

The 750 mg I.M. injection: mix the contents of one vial using 3 ml Sterile Water for injection to make an opaque suspension.
The 750 mg I.V. injection: dissolve the contents of one vial using 6 ml Sterile Water for injection to form a clear solution.
The 1.5 g I.V. injection: dissolve the contents of one vial using 15 ml Sterile Water for injection to form a clear solution.

The reconstituted suspension or solution is stable for 24 hours at room temperature (15 - 30 °C) and 48 hours in a refrigerator (2 - 8 °C).

THIS IS A MEDICAMENT

- Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you.
- Strictly follow the doctor's prescription, the method of use and the instructions of the pharmacist who sold the medicament.
- The doctor and the pharmacist are experts in medicine, its benefits and risks.
- Do not by yourself interrupt the period of treatment prescribed for you.
- Do not repeat the same prescription without consulting your doctor.

Keep medicament out of reach of children.

Council of Arab Health Ministers & Union of Arab Pharmacists.

Aug. 2002
24025/R1

Manufactured by:
TABUK PHARMACEUTICAL MANUFACTURING COMPANY,
P.O. Box 3633, TABUK, SAUDI ARABIA.